LY2228820

Catalog No.S1494

LY2228820 Chemical Structure

Molecular Weight(MW): 612.74

LY2228820 is a novel and potent inhibitor of p38 MAPK with IC50 of 7 nM in a cell-free assay, does not alter p38 MAPK activation. Phase 1/2.

Size Price Stock Quantity  
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • CD34 expression after 14 days of culture of CB CB CD34+ cells treated with the P38α inhibitor Ly2228820 or vehicle (DMSO; n=3). Error bars represent SEM.

    Blood 2012 119, 6255-8. LY2228820 purchased from Selleck.

    Cell cycle phase distributions were determined on U87EV and U87PTEN cell treated with B, +/- rapamycin and +/- LY2228820 as shown. Percent apoptotic cells as determined via annexin V staining is also shown below each graph. D were identical to B, except LN229MER-AKT and LN229EV cells induced with 4OHT were used.

    Mol Cancer Ther 2011 10, 2244-56. LY2228820 purchased from Selleck.

  • Cells were treated with 100-mU/mL bTSH with or without 1μM LY2228820. After 5 days, OPN expression (C) was determined by RT-qPCR. OPN secretion was determined by ELISA in cell culture medium. The bars represent the mean ± SEM of 3 experiments with at least 2 biological replicates.

    Endocrinology, 2016, 157(5):2173-81. LY2228820 purchased from Selleck.

    Relationship of JNK, p38 MAPK, and PI3K activation in TNF-α-induced signaling. Western blot analysis of the effect of another p38 MAPK inhibitor, LY2228820, on TNF-α signaling. HUVECs were pretreated with LY2228820 (10 umol/L) or wortmannin (1 umol/L) for 1 h, followed by stimulation with TNF-α (5 ng/mL) for 15 min (n=2).

    Acta Pharmacol Sin 2014 35, 339-50. LY2228820 purchased from Selleck.

  • For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of LY2228820 by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

    Dr. Yong-Weon Yi from Georgetown University Medical Center. LY2228820 purchased from Selleck.

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description LY2228820 is a novel and potent inhibitor of p38 MAPK with IC50 of 7 nM in a cell-free assay, does not alter p38 MAPK activation. Phase 1/2.
Targets
p38α [1]
(Cell-free assay)
7 nM
In vitro

LY2228820 inhibits p38α, as well as the level of phosphoMAPKAPK-2 (pMK2) in RAW 264.7 cells, with IC50 values of 7 nM and 34.3 nM, respectively. Furthermore, LY2228820 inhibits lipopolysaccharide (LPS)-induced TNFα formation in murine peritoneal macrophages, with IC50 of 5.2 nM. [1] In multiple myeloma (MM) cells, including INA6, RPMI-8226, U266, and RPMI-Dox40, LY2228820 (200 nM–800 nM) significantly blocks p38MAPK signaling, as revealed by its inhibition on phosphorylation of HSP27, a downstream target of p38MAPK, without affecting the expression level of HSP27. LY2228820 (200 nM–400 nM) enhances bortezomib-induced cytotoxicity and apoptosis, but LY2228820 alone doesn't inhibit the growth of MM.1S cells. LY2228820 (200 nM–800 nM) also inhibits secretion of IL-6 and MIP-1α in long-term BM stromal cells (LT-BMSCs), BM mononuclear cells (BMMNCs), peripheral blood (PB) CD138+, CD138 or PB CD14+ cells. LY2228820 (400 nM–800 nM) also blocks osteoclastogenesis from CD14+ cells. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
RPMI-8226 MXfLbY5ie2ViYYPzZZk> MUL+PFAxKG6P M2\3c2ROW09? NYTy[m05cW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEiVUEK3 NIXhTFEyQDN7N{O0OS=>
U266 NYWzeXVpU2mwYYPlJIF{e2G7 M3zNXJ45ODBibl2= NVK1NVZJTE2VTx?= MWLpcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gTHNROjd? NGPFV3IyQDN7N{O0OS=>
MM.1S MljsT4lv[XOnIHHzd4F6 NHnnd3J,QDByIH7N MkLDSG1UVw>? MVnpcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gTHNROjd? NGW1bIcyQDN7N{O0OS=>
RPMI-Dox40 M3viNGtqdmG|ZTDhd5NigQ>? NIrKclJ,QDByIH7N MnjWSG1UVw>? MmX1bY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGhUWDJ5 NXq5V5pTOTh|OUezOFU>
RPMI-LR5 NFfNd5pMcW6jc3WgZZN{[Xl? NEfyb21,QDByIH7N MWDEUXNQ Ml3vbY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGhUWDJ5 MXixPFM6PzN2NR?=
INA-6 MVnLbY5ie2ViYYPzZZk> MUL+PFAxKG6P MoLMSG1UVw>? MoPxbY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGhUWDJ5 NUfzV5pHOTh|OUezOFU>
RPMI-8226 MYDDfZRwgGmlaYT5JIF{e2G7 NVTjNlNChjFyMECgcm0> NILWRmlFVVOR MWPuc{B{cWewaX\pZ4FvfCCleYTveI95cWOrdIm= M{HGd|E5Ozl5M{S1
U266 MUDDfZRwgGmlaYT5JIF{e2G7 NYPqZYtQhjFyMECgcm0> NH7lZnZFVVOR NIPqdJlvdyC|aXfubYZq[2GwdDDjfZRwfG:6aXPpeJk> MVWxPFM6PzN2NR?=
MM.1S M3ThZWN6fG:6aXPpeJkh[XO|YYm= NVHPdo1xhjFyMECgcm0> MkLvSG1UVw>? M2jLSI5wKHOrZ37p[olk[W62IHP5eI91d3irY3n0fS=> MYGxPFM6PzN2NR?=
RPMI-Dox40 MoLCR5l1d3irY3n0fUBie3OjeR?= MUj+NVAxOCCwTR?= M1r4UWROW09? NXTUOJBvdm9ic3nncolncWOjboSgZ5l1d3SxeHnjbZR6 M2nPc|E5Ozl5M{S1
RPMI-LR5 MYjDfZRwgGmlaYT5JIF{e2G7 MlmxglExODBibl2= M17UWGROW09? NF;uVZhvdyC|aXfubYZq[2GwdDDjfZRwfG:6aXPpeJk> M1XGRVE5Ozl5M{S1
INA-6 NFzXU3ZEgXSxeHnjbZR6KGG|c3H5 NGPlT4R,OTByMDDuUS=> NHjCbHFFVVOR MXLuc{B{cWewaX\pZ4FvfCCleYTveI95cWOrdIm= M37IO|E5Ozl5M{S1
CD14+ NUXZTph7TnWwY4Tpc44h[XO|YYm= M37Cbp45ODBibl2= NWDDRmVVTE2VTx?= MWHpcohq[mm2czDvd5Rmd2OuYYP0c4dmdmW|aYOg[pJwdSCFREG0JJBwe2m2aY\lJINmdGy| M1zN[lE5Ozl5M{S1
U-87-MG MojLSpVv[3Srb36gZZN{[Xl? MVixJO69VQ>? NFfGU2JFVVOR NXnu[phLemWmdXPld{B1fW2xcj3kdol3\W5iY3;y[EBnd3KvYYTpc44> MX2yN|M{PTVyNh?=
MDA-MB-231 NVjCXGd1TnWwY4Tpc44h[XO|YYm= NFjzeJQyKM7:TR?= NWP4V4xPTE2VTx?= NGH6cXJz\WS3Y3XzJJR2dW:{LXTybZZmdiClb4LkJIZwem2jdHnvci=> M2fMeFI{OzN3NUC2
A-2780 MnLySpVv[3Srb36gZZN{[Xl? NXjOTHNnOSEQvF2= MUPEUXNQ M3fNVpJm\HWlZYOgeJVud3JvZILpeoVvKGOxcnSg[o9zdWG2aX;u Ml;0NlM{OzV3ME[=
SK-OV-3 MlfJSpVv[3Srb36gZZN{[Xl? MVKxJO69VQ>? NHu1S|lFVVOR NX3xOWVIemWmdXPld{B1fW2xcj3kdol3\W5iY3;y[EBnd3KvYYTpc44> M{nOcFI{OzN3NUC2
LXFA-629 MYjGeY5kfGmxbjDhd5NigQ>? NVjOcpdXOSEQvF2= M4ftVmROW09? M{nuU5Jm\HWlZYOgeJVud3JvZILpeoVvKGOxcnSg[o9zdWG2aX;u MkDLNlM{OzV3ME[=
NCI-H1650 MYDGeY5kfGmxbjDhd5NigQ>? MWSxJO69VQ>? M3X4RWROW09? MYny[YR2[2W|IIT1cY9zNWS{aY\lckBkd3KmIH\vdo1ifGmxbh?= MVeyN|M{PTVyNh?=
PC-3 M3XoWWZ2dmO2aX;uJIF{e2G7 M4PEN|Eh|ryP M3\ydGROW09? Mn7odoVlfWOnczD0eY1wei2mcnn2[Y4h[2:{ZDDmc5Ju[XSrb36= MkK4NlM{OzV3ME[=
RAW264.7 MkPvSpVv[3Srb36gZZN{[Xl? NFSxWG1,OjBizszN Mkn4SG1UVw>? NIK1WVdqdmirYnn0d{BCdmm|b335Z4lvNXO2aX31cIF1\WRiTVuyJJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOzVwMzDuUS=> NFrtZ4ozPDN3NkixOC=>
mouse peritoneal macrophages M2\aTGZ2dmO2aX;uJIF{e2G7 M4Gxdp4zOCEQvF2= NFLUVVJFVVOR MnrlUHBUN0mITj5Ot-KBm3O2aX31cIF1\WRiVF7GMe6yKHC{b3T1Z5Rqd25id3n0bEBKSzVyIH;mJFYvOyCwTR?= NUHI[3VbOjR|NU[4NVQ>
A549 MUjGeY5kfGmxbjDhd5NigQ>? M{PZc54zOCEQvF2= M1X3RWROW09? MljCbY5pcWKrdIOgUHBUNWmwZIXj[YQhS1iFTEigdJJw\HWldHnvckB4cXSqIFnDOVAhd2ZiMUS0Mlkhdk1? NWfVdFBJOjR|NU[4NVQ>
MDA-231 MW\GeY5kfGmxbjDhd5NigQ>? MXr+NVAh|ryP NXPpWIQ3e3WycILld5NmeyCGS1utNUBmgHC{ZYPzbY9v Mkj2NlY1ODd6NEO=
MCF-7 MWjGeY5kfGmxbjDhd5NigQ>? M{e3U54yOCEQvF2= NUT1RYlwe3WycILld5NmeyCGS1utNUBmgHC{ZYPzbY9v MUOyOlQxPzh2Mx?=
MDA-435 NHux[WNHfW6ldHnvckBie3OjeR?= M3HTbp4yOCEQvF2= NVPWRZFMe3WycILld5NmeyCGS1utNUBmgHC{ZYPzbY9v MkLoNlY1ODd6NEO=
PC3 MXTGeY5kfGmxbjDhd5NigQ>? MoLJglExKM7:TR?= NUjrd441TE2VTx?= NWj6UFRFe3WycILld5NmeyCGS1utNUBmgHC{ZYPzbY9v NY\ydWVGOjZ7MUO2NFg>

... Click to View More Cell Line Experimental Data

In vivo In LPS-induced mice, LY2228820 effectively inhibits the formation of TNFα with a threshold minimum 50% effective dose (TMED50) less than 1 mg/kg. In a rat model of collagen-inducedarthritis (CIA), LY2228820 displays potent effects on paw swelling, bone erosion, and cartilage destruction, with a threshold minimum 50% effective dose (TMED50)of 1.5 mg/kg. [1]

Protocol

Kinase Assay:[1]
+ Expand

Inhibition of p38α:

Inhibition of p38α is determined using recombinant human p38α in a standard filter binding protocol using ATP[γ-33P] and EGFR 21-mer peptide as substrate. Functional inhibition of TNFα in murine peritoneal macrophages is determined using LPS stimulation in the presence of LY2228820. To assess p38α activity in cells more directly, RAW 264.7 cells are treated with LY2228820 and then stimulated with anisomycin. The level of p38α activity is detected using a phosphoMAPKAPK-2 (pMK2) (Thr 334) antibody which reacts with a residue specifically phosphorylated by p38α.
Cell Research:[2, 3]
+ Expand
  • Cell lines: MM cells, including INA6, RPMI-8226, U266, and RPMI-Dox40
  • Concentrations: 200 nM–800 nM
  • Incubation Time: 48 hours
  • Method: MTT assays and APO 2.7 staining are performed to assess cellular proliferation and induction of apoptosis, respectively. Viability is expressed as percent viable cells. Apoptosis in cells is evaluated by APO 2.7 staining. For detection of mitochondrial membrane protein 7A6 expressed in apoptotic cells, cells are incubated with APO 2.7 reagent for 20 min. Expression of APO 2.7 is determined using an EPICS XL flow cytometer.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Lipopolysaccharide (LPS)-induced Balb/c mice
  • Formulation: Dissolved in 1% CMC/0.25% Tween 80 in water
  • Dosages: 0–20 mg/kg
  • Administration: Oral bid dosing for 14 days
    (Only for Reference)

Solubility (25°C)

In vitro Water 100 mg/mL warmed (163.2 mM)
DMSO 4 mg/mL warmed (6.52 mM)
Ethanol 3 mg/mL (4.89 mM)
In vivo Add solvents individually and in order:
Saline
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 612.74
Formula

C24H29FN6.2CH4O3S

CAS No. 862507-23-1
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02364206 Recruiting Adult Glioblastoma Centre Jean Perrin|National Cancer Institute, France|ARC Foundation for Cancer Research June 2015 Phase 1|Phase 2
NCT02322853 Recruiting Postmenopausal|Metastatic Breast Cancer Centre Francois Baclesse|National Cancer Institute, France|ARC Foundation for Cancer Research January 2015 Phase 2
NCT01663857 Active, not recruiting Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer Eli Lilly and Company July 2012 Phase 1|Phase 2
NCT01393990 Completed Advanced Cancer Eli Lilly and Company August 2008 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products

Tags: buy LY2228820 | LY2228820 supplier | purchase LY2228820 | LY2228820 cost | LY2228820 manufacturer | order LY2228820 | LY2228820 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID